SXTMEDIUM SIGNALFINANCIAL10-K

SXT's balance sheet expanded meaningfully through higher debt and inventory accumulation, while operating cash flow declined and capital expenditure grew substantially, signaling an investment-heavy cycle with tightening near-term cash generation.

The combination of rising total debt (+15.6%) and a meaningful drop in operating cash flow (-18.7%) suggests SXT is funding its growth initiatives increasingly through borrowing rather than internal cash generation, which warrants monitoring of leverage trajectory. The small bolt-on acquisition of Biolie SAS (natural color extraction, France) for $4.9 million net cash adds negligible strategic scale but confirms continued commitment to natural colors expansion. Investors should watch whether the elevated capital expenditure cycle translates into improved operating cash flow in subsequent periods, or whether the debt load continues to build.

Comparing 2026-02-13 vs 2025-02-19View on EDGAR →
FINANCIAL ANALYSIS

Total assets grew to $2.2B (+10.9%), driven by a meaningful build in inventory (+13%) and current assets (+12.4%), while stockholders' equity expanded modestly to $1.2B (+12.5%), suggesting the balance sheet remains solvent and growing. However, operating cash flow declined by $29.4M (-18.7%) to $127.8M while capital expenditure grew substantially to $89.4M, compressing free cash flow and indicating the business is in an active investment phase. Total debt rose to $709.2M (+15.6%), and while cash on hand improved modestly to $36.5M (+37.2%), the widening gap between debt and operating cash generation is the key metric for investors to track heading into the next filing period.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+51%
$59.2M→$89.4M

Capital expenditure jumped 51% — major investment cycle underway; assess returns on deployment.

Cash & Equivalents
Balance Sheet
+37.2%
$26.6M→$36.5M

Cash position surged 37.2% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
-18.7%
$157.2M→$127.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Debt
Balance Sheet
+15.6%
$613.5M→$709.2M

Debt rose 15.6% — additional borrowing for investment or operations; monitor coverage ratios.

Inventory
Balance Sheet
+13%
$600.3M→$678.2M

Inventory built 13% — monitor whether demand supports this build or if write-downs may follow.

Stockholders Equity
Balance Sheet
+12.5%
$1.1B→$1.2B

Equity base grew 12.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+12.4%
$961.9M→$1.1B

Current assets grew 12.4% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+10.9%
$2.0B→$2.2B

Asset base grew 10.9% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-19
ADDED
Exhibits and Financial Statement Schedules 61 List of Financial Statements and Financial Statement Schedule 61 Financial Statement Schedule 67 Schedule II Valuation and Qualifying Accounts 67 Item 16.
The Company s corporate expenses, share-based compensation (except for share-based compensation expense associated with stock grants to certain business unit leaders) , restructuring and other charges, including the Portfolio Optimization Plan costs, and certain other costs are included in the Corporate Other category as described in this report.
Acquisition On February 14, 2025, the Company acquired Biolie SAS , a natural color extraction business located in France.
The Company paid $4.9 million in cash for this acquisition, which is net of $0.2 million in debt assumed.
The assets acquired and liabilities assumed were recorded at their estimated fair value as of the acquisition date.
The Company acquired net assets of $0.3 million, with the remaining $4.6 million allocated to goodwill.
During 2025, the Company changed the name of its Sensient Natural Ingredients product line to Sensient Agricultural Ingredients to clearly distinguish it from the natural color activities within the Food Pharmaceutical Colors product line within the Color Group.
The Company sells dehydrated products to food manufacturers for use as ingredients and also for repackaging under private labels for sale to the retail market, quick service restaurants, and to the food service industry.
6 Index In 2025, the process of converting the United States food market from synthetic to natural colors gained significant momentum as a result of legislative action in various states, political support from the Trump administration, and announcements of commitments to eliminate synthetic food colorants by several major United States companies.
As a result of the aforementioned developments, the Company is in the process of accelerating its efforts to enable the conversion of its synthetic food color business in North America (of approximately $100 million in revenue) to natural colors.
REMOVED
Exhibits and Financial Statement Schedules 60 List of Financial Statements and Financial Statement Schedule 60 Financial Statement Schedule 66 Schedule II Valuation and Qualifying Accounts 66 Item 16.
The Company s corporate expenses, divestiture other related income, share-based compensation, restructuring and other charges, including the Portfolio Optimization Plan costs, and certain other costs are included in the Corporate Other category as described in this report.
Acquisitions On October 3, 2022, the Company acquired Endemix Do al Maddeler A.
(collectively, Endemix), a natural colors business located in Turkey.
The Company paid $23.3 million in cash for this acquisition, which is net of $1.3 million in debt assumed.
5 Index Divestitures In 2022, the Company received $2.5 million of net cash related to the previously completed sale of its yogurt fruit preparations product line.
The Company sells dehydrated products to food manufacturers for use as ingredients and also for repackaging under private labels for sale to the retail market and to the food service industry.
6 Index Asia Pacific Group The Asia Pacific Group focuses on marketing the Company s diverse product lines in the Pacific Rim under the Sensient name.
The Company s corporate expenses, divestiture other related income, share-based compensation, restructuring and other charges, including the Portfolio Optimization Plan costs, and other costs, are included in the Corporate Other category.
The Company employed 772 people in research and development, quality assurance, agronomy, quality control, and lab technician positions as of December 31, 2024.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →